Skip to content

Study · In vitro (cells) · 2022

1 result

Nicotinamide Mononucleotide Prevents Cisplatin-Induced Mitochondrial Defects in Cortical Neurons Derived from Human Induced Pluripotent Stem Cells.

Rashid MA, Oliveros A, Kim YS, Jang MH

Brain plasticity (Amsterdam, Netherlands)20 Dec 2022Cited by 10 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human cortical neurons, NMN pretreatment prevented cisplatin-induced mitochondrial defects.

    In plain wordsIn cells from human cortical neurons, NMN pretreatment prevented cisplatin-induced mitochondrial defects.

    Outcome
    DecreaseMitochondrial defects
    Study

    humann: not reported in source

    iPSC-derived cortical neurons exposed to cisplatin
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, pretreatment with NMN prevents cisplatin-induced defects in mitochondria of human cortical neurons.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.